Biggest Stock Movers Thursday: WBD, MRNA, SNOW, CRM, and More Stock Market : 27 Feb

Stock Market futures inched up on Thursday, driven by Nvidia’s impressive earnings report, although a rise in initial jobless claims to a three-month high of 242K and President Donald Trump’s remarks on tariffs kept investors cautious. Trump confirmed that tariffs on Canada and Mexico would proceed as planned, with additional tariffs set to be imposed on China.

Here’s a rundown of some of Thursday’s biggest Stock Movers

Biggest Stock Gainer

Snowflake (SNOW) +9%

Snowflake’s stock surged after the company reported stronger-than-expected fourth-quarter results and guidance. Revenue grew by 27% year-over-year, with product revenue up 28%. Although its Q1 product revenue guidance of $955 million to $960 million fell slightly short of the consensus estimate of $962.6 million, the company’s fiscal 2026 product revenue forecast of $4.28 billion topped expectations of $4.23 billion. Snowflake also announced an expanded partnership with Microsoft to integrate OpenAI models, along with an 8% adjusted operating margin.

Read More : Smart Saving How to Make the Most of Your $100,000 in Savings

Nexstar Media (NXST) +14%

Shares of Nexstar jumped after the company posted a 14.1% year-over-year increase in net revenue, driven by a 29.6% rise in advertising revenue. Net income margin expanded from 7.7% to 15.4%, while Q4 adjusted EBITDA surged by 39.9% to $628 million. The company also reduced debt by $327 million, improving its net leverage to 2.91x. Nexstar’s adjusted EBITDA guidance for fiscal 2025 is between $1.5 billion and $1.595 billion.

Warner Bros. Discovery (WBD) +9%

Despite missing analysts’ estimates, Warner Bros. Discovery shares climbed as the company forecast strong growth in its direct-to-consumer (DTC) business. Warner Bros. expects continued subscriber growth throughout 2025, with at least 150 million global subscribers by the end of 2026. The company also plans to expand its Max service into several new markets, including Australia in March 2025 and Germany and Italy in 2026. DTC revenue grew 6% to $2.65 billion in Q4, and total subscribers increased by 20% year-over-year.

Biggest Stock Losers

Salesforce (CRM) -5%

Salesforce shares dropped after the company reported mixed Q4 results and provided a weaker-than-expected outlook. The company forecasted fiscal year 2026 revenue between $40.5 billion and $40.9 billion, falling short of the $41.5 billion consensus. Q1 revenue guidance also came in lower than expected, with an estimated range of $9.71 billion to $9.76 billion, below the consensus of $9.91 billion. Earnings per share guidance of $2.53 to $2.55 was just above expectations of $2.53.

Teladoc Health (TDOC) -15%

Teladoc’s stock plummeted after the company missed Q4 earnings expectations and issued a weak outlook. The company’s Q1 revenue guidance of $608 million to $629 million, with a midpoint of $618.5 million, fell short of the consensus estimate of $633.03 million. For FY2025, Teladoc’s revenue outlook of $2.468 billion to $2.576 billion also lagged expectations, while its EPS guidance of -$1.10 to -$0.50 missed the consensus of -$1.03.

eBay (EBAY) -8%

Despite beating Q4 estimates, eBay’s stock fell due to weak guidance. The company expects Q1 revenue between $2.52 billion and $2.56 billion, with a midpoint of $2.54 billion, below the $2.59 billion consensus. Adjusted EPS guidance of $1.32 to $1.36 also slightly missed the consensus of $1.33, and its forecasted gross merchandise value (GMV) of $18.3 billion to $18.6 billion is lower than the $19.3 billion in Q4.

Moderna (MRNA) -7%

Moderna shares slipped after reports surfaced that U.S. health officials were reassessing a $590 million bird flu vaccine contract granted to the company. The review is part of a broader reassessment of spending on messenger RNA vaccines, including Moderna’s COVID-19 shot. The contract, awarded in the final days of the Biden administration, is now under scrutiny as officials reconsider future funding for vaccine makers. Moderna’s plans for a late-stage study of its pandemic flu vaccine may be at risk if funding is pulled.

Viatris (VTRS) -17%

Viatris’ stock tanked after the company missed Q4 estimates and provided a disappointing full-year outlook. The company cited ongoing remediation work at its India plant, which has impacted U.S. pharmaceutical imports. Viatris expects a $500 million hit to revenue and a $385 million impact on adjusted EBITDA in 2025. Its fiscal year 2025 guidance of $13.75 billion in revenue and $2.19 adjusted EPS fell short of consensus estimates, sending shares down sharply.

Follow our youtube channel, click here .